Hypoparathyroidism Treatment Market

Hypoparathyroidism is a rare disorder characterized by the underactivity of the parathyroid glands. The condition is typically caused by a deficiency or dysfunction of thyroid hormones, which regulate calcium and phosphorus levels in the blood. Due to its rarity, hypoparathyroidism treatment is a largely unmet need. This presents an opportunity for key players in the hypoparathyroidism treatment market to invest in innovative products and services that would address this unmet need. In this report, we provide you with a comprehensive analysis of the hypoparathyroidism treatment market, as well as our top three key players.

These companies are engaged in developing and marketing various types of hypoparathyroidism treatments. Some of the key products produced by these companies include calcitonin gene-related peptide (CGRP) antagonists such as gabapentin (Neurontin), pregabalin (Lyrica), and phenytoin sodium benzoate (Dilantin) for neuropathic pain management; immunomodulators such as thymosins for autoimmune diseases; inhibitors of thyroid peroxidase such as propylthiouracil or methimazole for managing hyperthyroidism; hormone replacement therapies, such as Replacement Therapy With Levothyrox.

The hypoparathyroidism treatment market is expected to grow at a CAGR of **% during the forecast period of 2018–2031.

Some of the key players in this market are Shire NPS Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Entera Bio Ltd., Amgen Inc., Ascendis Pharma A/S, F. Hoffmann-La Roche Ltd., ProLynx, Inc., Extended Biosciences, Inc., BionPharma, Inc., and F Hoffmann-La Roche Ltd.